Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (DE:3ZO)
FRANKFURT:3ZO
RESEARCH TOOLSreports
Holding DE:3ZO?
Track your performance easily
3ZO Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.21 - €5.55
Previous Close€1.87
Volume0.00
Average Volume (3M)N/A
Market Cap
€31.19M
Enterprise Value€25.40M
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Nov 12, 2024EPS Estimate
-€0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,245,099
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)10.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
€9.90Price Target Upside428.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Acurx Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsIbezapolstat demonstrated a pooled clinical cure rate of 96% across two Phase 2 studies in CDI patients, showcasing its potential as a highly effective treatment option.
Regulatory ProgressManagement announced a successful end-of-Phase 2 meeting with the FDA and agreement on what a Phase 3 program should entail, indicating readiness to proceed to the next critical stage of drug development.
Strategic PartnershipsManagement is considering strategic partnerships that could provide additional capital and facilitate market entry in the EU or Japan, highlighting the company's proactive approach to global expansion and commercialization.
Bears Say
Clinical Trial RisksRisks include potential failure in the Phase 3 trial, challenges in securing regulatory approval, and the possibility of a smaller than anticipated commercial opportunity.
Drug Development DelaysThe company has moderated its price target due to an updated timeline for the Phase 3 trials start.
Financial PerformanceAcurx reported a 1Q24 net loss of $4.4M with total cash standing at $8.9M, indicating a need for careful financial management moving forward.
---
Options Prices
Currently, No data available
---
Ownership Overview
13.42% Insiders
3.74% Mutual Funds
5.14% Other Institutional Investors
77.70% Public Companies and
Individual Investors
3ZO FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was €1.21 and its highest was €5.55 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Currently, no data Available
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Nov 12, 2024 which is in 65 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Aug 09, 2024. The company reported -€0.235 earnings per share for the quarter, missing the consensus estimate of -€0.149 by -€0.086.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -€0.13.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 16,245,098 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -€0.235 in its last earnings report, missing expectations of -€0.149. Following the earnings report the stock price went down -0.571%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3ZO
---
Acurx Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.90 (428.82% Upside)
€9.90 (428.82% Upside)
Blogger Sentiment
Bullish
DE:3ZO Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.50%
12-Months-Change
Fundamentals
Return on Equity
-346.94%
Trailing 12-Months
Asset Growth
-28.75%
Trailing 12-Months
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
---
3ZO Earnings Call
Q2 2024
0:00 / 0:00
---
3ZO Stock 12 Month Forecast
Average Price Target
€9.90
▲(428.82% Upside)
Technical Analysis
Acurx Pharmaceuticals
―
TRACON Pharmaceuticals
―
Atea Pharmaceuticals
―
Chimerix
―
Aurinia Pharmaceuticals
―
Best Analysts Covering 3ZO
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-13.24%
reiterated a buy rating 27 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -13.24% per trade.
---